Key result
Empirical statistical models and historical cohort data are used to compare cholinesterase inhibitor-treated and untreated Alzheimer's patients in long-term studies where placebo is unethical.
Why the study?
How can long-term outcomes of cholinesterase inhibitors in Alzheimer's disease be assessed when placebo-controlled studies are not permitted?
How can long-term outcomes of cholinesterase inhibitors in Alzheimer's disease be assessed when placebo-controlled studies are not permitted?
This review highlights the necessity and limitations of using mathematical models and historical data to evaluate long-term Alzheimer's disease treatments when placebo controls are unethical.
Answers are grounded in this paper and cite their sources.
Modeling enables ethical long-term cholinesterase inhibitor assessment in Alzheimer's; leaves open validity without prospective confirmation.
In Alzheimer's disease (AD), placebo-controlled long-term studies of cholinesterase inhibitors (ChEIs) are not permitted for ethical reasons. Therefore, in these studies, patients' outcomes on cognitive and functional assessment scales must be compared with mathematical models or historical data from untreated cohorts. PubMed and previously published long-term extensions of clinical trials and naturalistic studies of ChEIs were examined to identify empirical statistical models and other approaches, such as use of data from historical cohorts or extrapolated changes from extension studies, that were used to draw comparisons between ChEI-treated and untreated patients. The models and methods were described. It is essential to be aware of the limitations of comparisons made with these approaches. Prediction models based on ChEI-treated patients can be used in the studies of new treatments when those treatments are added to ChEIs. More sophisticated models that also accommodate patient-specific characteristics should be developed for comparisons in future long-term AD studies.
No takes yet. Share an insight, caveat, or question.
Carina Wattmo (2013) conducted a review in Alzheimer's disease. Prediction models and historical data vs. Untreated cohorts was evaluated. Empirical statistical models and historical cohort data are used to compare cholinesterase inhibitor-treated and untreated Alzheimer's patients in long-term studies where placebo is unethical.
Synapse has enriched 10 related papers. Consider them for comparative context: